KR102100103B1 - Aqueous pectin solution - Google Patents
Aqueous pectin solution Download PDFInfo
- Publication number
- KR102100103B1 KR102100103B1 KR1020147034505A KR20147034505A KR102100103B1 KR 102100103 B1 KR102100103 B1 KR 102100103B1 KR 1020147034505 A KR1020147034505 A KR 1020147034505A KR 20147034505 A KR20147034505 A KR 20147034505A KR 102100103 B1 KR102100103 B1 KR 102100103B1
- Authority
- KR
- South Korea
- Prior art keywords
- pectin
- aqueous solution
- calcium
- solution
- viscosity
- Prior art date
Links
- 239000001814 pectin Substances 0.000 title claims abstract description 199
- 229920001277 pectin Polymers 0.000 title claims abstract description 199
- 235000010987 pectin Nutrition 0.000 title claims abstract description 199
- 239000007864 aqueous solution Substances 0.000 claims abstract description 119
- 239000011575 calcium Substances 0.000 claims abstract description 62
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 60
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 60
- 235000015097 nutrients Nutrition 0.000 claims abstract description 58
- 239000000243 solution Substances 0.000 claims abstract description 46
- 230000032050 esterification Effects 0.000 claims abstract description 26
- 238000005886 esterification reaction Methods 0.000 claims abstract description 26
- 239000011259 mixed solution Substances 0.000 claims abstract description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000001110 calcium chloride Substances 0.000 claims abstract description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 4
- 239000001509 sodium citrate Substances 0.000 claims abstract description 4
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims abstract description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 210000002784 stomach Anatomy 0.000 claims description 8
- 239000011734 sodium Substances 0.000 abstract description 36
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 34
- 229910052708 sodium Inorganic materials 0.000 abstract description 34
- 238000003860 storage Methods 0.000 abstract description 10
- 239000013049 sediment Substances 0.000 abstract description 8
- 230000000052 comparative effect Effects 0.000 description 21
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 12
- 230000008719 thickening Effects 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 208000008279 Dumping Syndrome Diseases 0.000 description 5
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- -1 organic acid salt Chemical class 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/231—Pectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
나트륨 함유량이 180 ㎎/100 ㎖ 이상인 경장 영양제라도 증점시킬 수 있어, 보존 중에 침전물이 발생하지 않는 펙틴 수용액을 제공한다. 이 펙틴 수용액은 에스테르화도 5 ∼ 15 ％, 점도 평균 분자량이 10000 ∼ 35000 인 펙틴을 함유한다. 펙틴 수용액의 칼슘 농도는 9 ppm 이하, 펙틴 수용액의 점도 (25 ℃) 는 1 ∼ 30 mPa·s 이다. 펙틴 수용액 100 ㎖ 와, 염화칼슘 0.019 ㏖/ℓ, 시트르산나트륨 0.020 ㏖/ℓ 의 칼슘·나트륨 수용액 200 ㎖ 의 혼합액의 점도 (25 ℃) 가 700 ∼ 10000 mPa·s 이다.Even enteric nutrients having a sodium content of 180 mg / 100 ml or more can be thickened, thereby providing an aqueous solution of pectin that does not generate sediment during storage. This aqueous pectin solution contains pectin having an esterification degree of 5 to 15% and a viscosity average molecular weight of 10000 to 35000. The calcium concentration of the pectin aqueous solution is 9 ppm or less, and the viscosity (25 ° C) of the pectin aqueous solution is 1 to 30 mPa · s. The viscosity (25 ° C.) of a mixed solution of 200 ml of a calcium-sodium aqueous solution of 100 ml of a pectin aqueous solution, 0.019 mol / L of calcium chloride, and 0.020 mol / L of sodium citrate is 700 to 10000 mPa · s.
Description
본 발명은 경장 영양제의 증점제로서 유용한 펙틴 수용액에 관한 것이다.The present invention relates to an aqueous pectin solution useful as a thickener for enteral nutrients.
음식이나 음료를 경구 섭취하는 것이 불가능한 자 혹은 곤란한 자에게 영양을 보급하기 위해서 경관 영양법이 실시되고 있다. 경관 영양법에는, 코로부터 위로 튜브를 통하여 경장 영양제를 투여하는 경비 위관법과, 복부에 누공을 형성하고, PEG 튜브를 이용하여 경장 영양제를 투여하는 위루가 있으며, 어느 경우나 경장 영양제는 경관 투여가 가능한 점도의 액체이기 때문에, 위 내에 투여된 경장 영양제가 식도로 역류하여 구토를 일으키거나, 장에 급속하게 유입되어 설사나 덤핑 증후군을 일으키거나 하는 것이 문제가 된다. 특히, 경비 위관법에서는 가는 튜브를 통과하도록 경장 영양제가 저점도로 조정되기 때문에, 식도로의 역류, 설사, 덤핑 증후군이 문제가 된다.In order to supply nutrition to those who cannot or cannot consume food or drink orally, landscape nutrition is being implemented. In the cervical nutrition method, there are a nasal gastrointestinal method in which enteral nutrients are administered through a tube from the nose to the stomach, and a gastric fistula that forms a fistula in the abdomen and administers a enteral nutrient using a PEG tube. Since it is a liquid of viscosity, it is a problem that enteral nutrients administered in the stomach reflux into the esophagus, causing vomiting, or rapidly entering the intestine to cause diarrhea or dumping syndrome. Particularly, in the nasogastric gavage method, reflux, diarrhea, and dumping syndrome of the esophagus become a problem because the enteral nutrient is adjusted to a low viscosity to pass through a thin tube.
그래서, 경장 영양제의 역류, 설사, 덤핑 증후군을 방지하기 위해서, 위 내에서 경장 영양제를 증점시키는 저메톡실펙틴 수용액 등의 증점제가 사용되고 있다 (특허문헌 1, 2). 저메톡실펙틴은 펙틴을 구성하는 갈락투론산 중 메틸에스테르화한 것의 비율인 에스테르화도 (DE) 가 50 ％ 미만이고, 칼슘 이온 등의 2 가 금속 이온의 존재로 겔을 형성한다.Therefore, in order to prevent reflux, diarrhea, and dumping syndrome of enteric nutrients, thickeners such as aqueous solutions of low methoxylfectin that thicken enteric nutrients in the stomach are used (Patent Documents 1 and 2). Low methoxyl pectin has a degree of esterification (DE) of less than 50%, which is the ratio of methyl esterification of galacturonic acid constituting pectin, and forms a gel in the presence of divalent metal ions such as calcium ions.
한편, 종래 경장 영양제로는 나트륨 함유량이 150 ㎎/100 ㎖ 이하인 것이 많이 사용되고 있지만, 경장 영양제의 장기간 투여에 수반되는 저나트륨혈증을 예방하기 위해서, 나트륨 함유량을 보다 많이 한 경장 영양제, 특히 나트륨 농도가 180 ㎎/100 ㎖ 이상인 경장 영양제도 사용되게 되어 있다.On the other hand, conventionally enteral nutrients, sodium content of 150 mg / 100 ml or less is often used, but in order to prevent hyponatremia accompanying long-term administration of enteric nutrients, enteral nutrients with a higher sodium content, especially sodium concentration Intestinal nutrients over 180 mg / 100 ml are also expected to be used.
그러나, 나트륨 함유량이 많은 경장 영양제는 종전의 저메톡실펙틴으로는 증점되지 않는다는 문제가 있다. 이에 대하여 저메톡실펙틴의 에스테르화도를 보다 저감시키는 것이나 저메톡실펙틴의 함유량을 늘리는 것을 생각할 수 있지만, 저메톡실펙틴의 에스테르화도를 저감시키면 저메톡실펙틴수용액의 보존 중에 침전물이 발생해 버린다. 한편, 저메톡실펙틴의 함유량을 늘리면, 저메톡실펙틴 수용액의 점도가 높아지기 때문에, 경비 위관과 같은 가는 튜브를 통과시킬 때에, 시린지를 이용하여 주입하는 의료 종사자의 부담이 증가하게 된다.However, there is a problem that enteric nutrients with a high sodium content are not thickened with the conventional low methoxylfectin. On the other hand, it can be considered that the esterification degree of low methoxyl pectin is further reduced or the content of low methoxyl pectin can be increased, but when the esterification degree of low methoxyl pectin is reduced, a precipitate is generated during storage of the low methoxyl pectin aqueous solution. On the other hand, if the content of low methoxyl pectin is increased, the viscosity of the aqueous solution of low methoxyl pectin increases, which increases the burden of medical workers injecting with a syringe when passing a thin tube such as a nasogastric tube.
그래서, 본 발명은 나트륨 함유량이 180 ㎎/100 ㎖ 이상으로 고농도로 나트륨을 함유하는 경장 영양제라도 증점시킬 수 있어, 가는 튜브에 의한 경관 투여에 적절한 점도이며, 보존 중에 침전물이 발생하지 않는 펙틴 수용액의 제공을 목적으로 한다.Therefore, the present invention is capable of thickening even enteric nutrients containing sodium at a high concentration of 180 mg / 100 ml or more, which is suitable for intraocular administration by a thin tube, and is suitable for an aqueous solution of pectin that does not generate sediment during storage. It is aimed at providing.
본 발명은 펙틴 수용액에 사용하는 펙틴의 에스테르화도와 분자량을 특정 범위로 하고, 또한 펙틴 수용액에 함유되는 칼슘 농도를 특정 범위 이하로 하면, 상기 서술한 목적을 달성할 수 있는 것을 알아내고, 본 발명을 완성시켰다.The present invention finds out that the above-mentioned object can be achieved by setting the esterification degree and molecular weight of pectin used in the pectin aqueous solution to a specific range and the calcium concentration contained in the pectin aqueous solution to a specific range or less. Was completed.
즉, 본 발명은 에스테르화도 5 ∼ 15 ％, 점도 평균 분자량이 10000 ∼ 35000 인 펙틴을 함유하는 펙틴 수용액으로서, 펙틴 수용액의 칼슘 농도가 9 ppm 이하, 펙틴 수용액의 점도 (25 ℃) 가 1 ∼ 30 mPa·s 이며, 그 펙틴 수용액 100 ㎖ 와, 염화칼슘 0.019 ㏖/ℓ, 시트르산나트륨 0.020 ㏖/ℓ 의 칼슘·나트륨 수용액 200 ㎖ 의 혼합액의 점도 (25 ℃) 가 700 ∼ 10000 mPa·s 가 되는 펙틴 수용액을 제공한다.That is, the present invention is a pectin aqueous solution containing pectin having an esterification degree of 5 to 15% and a viscosity average molecular weight of 10000 to 35000, wherein the pectin aqueous solution has a calcium concentration of 9 ppm or less, and the pectin aqueous solution has a viscosity (25 ° C) of 1 to 30. mPa · s, a pectin aqueous solution having a viscosity (25 ° C) of 700 to 10000 mPa Gives
또, 본 발명은 상기 서술한 펙틴 수용액으로 이루어지는 경관 투여용 증점제를 제공한다.In addition, the present invention provides a thickener for cervical administration comprising the above-described aqueous pectin solution.
또한, 본 발명은 상기 서술한 펙틴 수용액의 제조 방법으로서, 에스테르화도 5 ∼ 15 ％ 의 펙틴으로서, 그 펙틴을 물로 희석시켜 펙틴 함유량 1 ∼ 5 질량％ 의 펙틴 수용액을 조제했을 경우에, 그 펙틴 수용액의 칼슘 농도가 9 ppm 이하가 되는 펙틴을 물로 희석시켜 펙틴 수용액의 점도 (25 ℃) 를 1 ∼ 30 mPa·s 로 조정하는 방법을 제공한다.In addition, the present invention is a method for producing a pectin aqueous solution as described above, and when the pectin is diluted with water to prepare a pectin aqueous solution having a pectin content of 1 to 5 mass% as a pectin having an esterification degree of 5 to 15%, the aqueous pectin solution Provided is a method for adjusting the viscosity (25 ° C.) of a pectin aqueous solution to 1 to 30 mPa · s by diluting pectin having a calcium concentration of 9 ppm or less with water.
본 발명의 펙틴 수용액에 의하면, 종래의 나트륨 함유량 150 ㎎/100 ㎖ 이하의 경장 영양제뿐만 아니라, 나트륨 함유량이 보다 많은 경장 영양제, 특히 나트륨 함유량 180 ㎎/100 ㎖ 이상의 경장 영양제라도 증점시킬 수 있어, 위 내에 투여된 경장 영양제의 역류, 설사, 덤핑 증후군을 방지할 수 있다.According to the aqueous solution of pectin of the present invention, not only a conventional enteric nutrient with a sodium content of 150 mg / 100 ml or less, but also a enteric nutrient with a higher sodium content, particularly a enteric nutrient with a sodium content of 180 mg / 100 ml or more, can be thickened. It can prevent reflux, diarrhea and dumping syndrome of enteral nutrients administered within.
또, 본 발명의 펙틴 수용액에 의하면, 보존 중에 침전물이 잘 생기지 않기 때문에, 사용자는 안심하고 사용할 수 있다.Further, according to the aqueous solution of pectin of the present invention, a precipitate is hardly formed during storage, so that the user can use it with confidence.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 펙틴 수용액은 주성분으로서 에스테르화도 (DE) 5 ∼ 15 ％ 의 저메톡실펙틴을 함유한다. 본 발명의 펙틴 수용액에 의하면, 펙틴의 에스테르화도가 15 ％ 이하로 낮고 칼슘 반응성이 높음으로써, 점도 평균 분자량이 10000 ∼ 35000, 바람직하게는 12000 ∼ 27000 으로 조절하는 것과 더불어, 펙틴 수용액의 점도가 30 mPa·s 이하로 낮으면서도, 경장 영양제가 나트륨 함유량 180 ㎎/100 ㎖ 이상으로 고나트륨 농도인 경우라도, 또 나트륨 함유량이 그보다 낮은 경우라도, 경장 영양제를 이 펙틴 수용액과 혼합함으로써, 그 경장 영양제를 증점시켜 위 내에 투여된 경장 영양제의 역류, 설사, 덤핑 증후군을 방지할 수 있다. 보다 구체적으로는, 예를 들어 나트륨을 180 ∼ 220 ㎎/100 ㎖ 의 고농도로 함유하는 경장 영양제 100 ㎖ 에 대하여 본 발명의 펙틴 수용액을 10 ∼ 100 ㎖ 첨가함으로써, 혼합액의 점도 (25 ℃) (BH 형 점도계) 를 600 ∼ 10000 mPa·s, 바람직하게는 800 ∼ 3000 mPa·s 로 할 수 있다.The aqueous pectin solution of the present invention contains, as a main component, low methoxyl pectin having an esterification degree (DE) of 5 to 15%. According to the aqueous solution of pectin of the present invention, the esterification degree of pectin is lower than 15% and the calcium reactivity is high, so that the viscosity average molecular weight is adjusted to 10000 to 35000, preferably 12000 to 27000, and the viscosity of the pectin aqueous solution is 30. The enteric nutrient is mixed with the aqueous solution of pectin by mixing the enteric nutrient with an aqueous solution of pectin, even if it is as low as mPa · s or less, even when the enteric nutrient is a sodium content of 180 mg / 100 ml or more and has a high sodium concentration. Thickening can prevent reflux, diarrhea, and dumping syndrome of enteral nutrients administered in the stomach. More specifically, for example, by adding 10 to 100 ml of the pectin aqueous solution of the present invention to 100 ml of enteric nutrients containing sodium at a high concentration of 180 to 220 mg / 100 ml, the viscosity of the mixed solution (25 ° C) (BH Mold viscometer) can be 600 to 10000 mPa · s, preferably 800 to 3000 mPa · s.
한편, 본 발명의 펙틴 수용액에 있어서, 펙틴의 에스테르화도는 지나치게 낮으면 칼슘 이온과의 반응시에 강고한 불용성의 겔이 되어 소화 흡수면에서 바람직하지 않기 때문에 5 ％ 이상으로 한다. 적당한 점도로 증점시키는 점에서, 펙틴 수용액의 에스테르화도를 5 ∼ 15 ％, 보다 바람직하게는 6 ∼ 13 ％ 로 한다. 에스테르화도가 15 ％ 보다 지나치게 높으면 펙틴 수용액의 칼슘 이온과의 반응성이 낮아, 경장 영양제를 충분히 증점시킬 수 없다.On the other hand, in the aqueous solution of pectin of the present invention, if the degree of esterification of pectin is too low, it becomes a highly insoluble gel upon reaction with calcium ions, and is 5% or more because it is not preferable in terms of digestion and absorption. From the point of thickening to a suitable viscosity, the degree of esterification of the pectin aqueous solution is 5 to 15%, more preferably 6 to 13%. When the degree of esterification is more than 15%, the reactivity of the pectin aqueous solution with calcium ions is low, and the enteric nutrient cannot be sufficiently thickened.
또한, 펙틴 수용액의 에스테르화도는 알칼리 용액에 의한 적정법 등으로 측정할 수 있다.In addition, the degree of esterification of the pectin aqueous solution can be measured by a titration method with an alkali solution or the like.
또, 본 발명의 펙틴 수용액이 주성분으로 하는 펙틴은 점도 평균 분자량이 10000 ∼ 35000, 바람직하게는 12000 ∼ 27000 이다. 여기서, 점도 평균 분자량은 극한 점도법에 의해 산출되는 평균 분자량이다. 펙틴의 점도 평균 분자량이 지나치게 크면 칼슘 이온과의 반응에 의해 강고한 불용성의 겔이 생성되어 소화 흡수면에서 바람직하지 않다. 적당한 점도로 증점시키는 점에서, 펙틴 수용액의 점도 평균 분자량을 35000 이하, 바람직하게는 27000 이하, 보다 바람직하게는 16000 이하로 한다. 반대로 점도 평균 분자량이 지나치게 작으면, 펙틴 수용액의 칼슘 이온과의 반응성이 낮아, 경장 영양제를 충분히 증점시킬 수 없기 때문에, 점도 평균 분자량은 10000 이상, 바람직하게는 12000 이상, 보다 바람직하게는 14000 이상이다. 또, 펙틴의 점도 평균 분자량을 상기 서술한 범위로 함으로써, 펙틴 수용액의 점도를 경관 투여에 적절한 30 mPa·s (25 ℃) 이하로 조정하는 것이 용이해진다.Moreover, the pectin which the pectin aqueous solution of this invention has as a main component has a viscosity average molecular weight of 10000-35000, Preferably it is 12000-27000. Here, the viscosity average molecular weight is an average molecular weight calculated by an infinite viscosity method. When the viscosity average molecular weight of pectin is too large, a strong insoluble gel is generated by reaction with calcium ions, which is not preferable in terms of digestion and absorption. The viscosity average molecular weight of the pectin aqueous solution is 35000 or less, preferably 27000 or less, and more preferably 16000 or less from the point of thickening to a suitable viscosity. Conversely, if the viscosity average molecular weight is too small, the reactivity of the pectin aqueous solution with calcium ions is low and the intestinal nutrient cannot be sufficiently thickened, so the viscosity average molecular weight is 10000 or more, preferably 12000 or more, and more preferably 14000 or more. . Moreover, by making the viscosity average molecular weight of pectin into the above-mentioned range, it becomes easy to adjust the viscosity of the pectin aqueous solution to 30 mPa * s (25 degreeC) or less suitable for landscape administration.
본 발명의 펙틴 수용액이 함유하는 펙틴은, 상기 서술한 바와 같이 에스테르화도 5 ∼ 15 ％, 점도 평균 분자량이 10000 ∼ 35000, 바람직하게는 12000 ∼ 27000 임으로써, 이 펙틴 수용액과 경장 영양제를 혼합한 경우에, 그 혼합액 중의 칼슘 이온 농도가 10 ppm 이상이면, 펙틴 수용액의 점도가 경관 투여에 적절한 30 mPa·s (25 ℃) 이하라도 혼합액의 점도가 600 mPa·s 이상으로 증점된다. 경장 영양제의 칼슘 이온 농도는 적어도 10 ppm 이상이기 때문에, 본 발명의 펙틴 수용액에 의해 경장 영양제를 증점시키는 것이 가능해진다.When the pectin contained in the aqueous pectin solution of the present invention has an esterification degree of 5 to 15% and a viscosity average molecular weight of 10000 to 35000, preferably 12000 to 27000, as described above, when the pectin aqueous solution and enteric nutrient are mixed In the case where the calcium ion concentration in the mixed solution is 10 ppm or more, the viscosity of the mixed solution is increased to 600 mPa · s or more, even if the viscosity of the pectin aqueous solution is 30 mPa · s (25 ° C.) or less suitable for cervical administration. Since the calcium ion concentration of the enteric nutrient is at least 10 ppm or more, it becomes possible to thicken the enteric nutrient by the aqueous solution of pectin of the present invention.
이와 같은 본 발명의 펙틴 수용액의 증점 작용은, 본 발명의 펙틴 수용액 100 ㎖ 와, 염화칼슘 0.019 ㏖/ℓ, 시트르산삼나트륨 0.020 ㏖/ℓ 의 칼슘·나트륨 수용액 200 ㎖ 를 30 초간 교반하고, 펙틴 수용액과 칼슘·나트륨 수용액을 혼합하고 나서 5 분 후의 점도 (25 ℃) 를 BH 형 점도계로 20 rpm, 액온 25 ℃ 에서 측정한 경우에, 700 ∼ 10000 mPa·s, 바람직하게는 1400 ∼ 8000 mPa·s 가 됨으로써 종전의 펙틴 수용액과 구별된다. 또한, 이 칼슘·나트륨 수용액에 있어서의 칼슘 함유량과 나트륨 함유량은 범용되고 있는 경장 영양제의 칼슘 함유량과 나트륨 함유량으로 되어 있고, 펙틴 수용액을 경장 영양제와 혼합했을 경우의 증점 작용을 조사하기 위해서 사용된다. 종전의 펙틴 수용액을 이 칼슘·나트륨 수용액과 혼합한 경우에는, 상기 점도 범위가 되지 않는다.Such a thickening action of the aqueous solution of pectin of the present invention is 100 ml of the aqueous solution of pectin of the present invention, 200 ml of calcium and sodium aqueous solution of 0.019 mol / l of calcium chloride and 0.020 mol / l of trisodium citrate, stirred for 30 seconds, and the aqueous solution of pectin When the viscosity (25 ° C.) after 5 minutes of mixing the aqueous solution of calcium and sodium is measured with a BH viscometer at 20 rpm and a liquid temperature of 25 ° C., 700 to 10000 mPa · s, preferably 1400 to 8000 mPa · s By this, it is distinguished from the previous aqueous pectin solution. In addition, the calcium content and the sodium content in this aqueous calcium / sodium solution are the calcium content and the sodium content of general-purpose enteric nutrients, and are used to investigate the thickening action when the pectin aqueous solution is mixed with the enteric nutrient. When the conventional aqueous pectin solution is mixed with this aqueous calcium / sodium solution, the viscosity range does not fall.
또, 본 발명의 펙틴 수용액은 점도 (25 ℃) 가 30 mPa·s 이하, 바람직하게는 10 mPa·s 이하이다. 펙틴 수용액의 점도가 지나치게 높으면, 경관 투여에서 사용되는 내경 1 ∼ 5 ㎜ 정도의 튜브를 통하여 펙틴 수용액을 투여하는 것이 곤란해지지만, 펙틴 수용액의 점도를 상기 서술한 범위로 함으로써 펙틴 수용액은 경관 투여에 적절한 것이 되고, 특히 경비 위관법에서도 바람직하게 사용할 수 있는 것이 된다. 또한, 경장 영양제를 적당히 증점시키는 점에서, 본 발명의 펙틴 수용액의 점도 (25 ℃) 는 1 mPa·s 이상으로 한다.Further, the aqueous solution of pectin of the present invention has a viscosity (25 ° C) of 30 mPa · s or less, preferably 10 mPa · s or less. When the viscosity of the aqueous pectin solution is too high, it is difficult to administer the aqueous pectin solution through a tube having an inner diameter of about 1 to 5 mm used in the field administration, but by setting the viscosity of the pectin aqueous solution to the above-described range, the aqueous pectin solution is administered It becomes suitable, and it can be used suitably also in the guardianship law. In addition, the viscosity (25 ° C) of the pectin aqueous solution of the present invention is 1 mPa · s or more from the viewpoint of appropriately thickening the enteric nutrient.
본 발명의 펙틴 수용액에 있어서, 펙틴의 함유량은 펙틴 수용액의 점도가 상기 서술한 범위가 되도록 펙틴의 분자량 등에 따라 적절히 조정할 수 있고, 예를 들어 펙틴의 점도 평균 분자량이 10000 ∼ 35000 인 경우, 1 ∼ 5 질량％ 로 하면 된다. 펙틴의 함유량이 지나치게 적으면 경장 영양제를 충분히 증점시킬 수 없고, 반대로 지나치게 많으면 경장 영양제와의 반응에서 강고한 겔이 생성되므로, 소화 흡수면에서 바람직하지 않다.In the pectin aqueous solution of the present invention, the content of pectin can be appropriately adjusted according to the molecular weight of pectin and the like so that the viscosity of the pectin aqueous solution is within the above-mentioned range, for example, when the viscosity average molecular weight of pectin is 10000 to 35000, 1 to It should just be 5 mass%. If the content of pectin is too small, the intestinal nutrient cannot be sufficiently thickened. On the contrary, when the content of pectin is too large, a strong gel is generated in reaction with the intestinal nutrient, which is not preferable in terms of digestion and absorption.
본 발명의 펙틴 수용액에서는 칼슘 농도가 9 ppm 이하로 낮은 것도 특징으로 하고 있다. 종래의 에스테르화도가 10 ％ 정도인 저메톡실펙틴은 칼슘을 1000 ppm 이상 함유하기 때문에, 저메톡실펙틴을 1 질량％ 수용액이 되도록 희석시킨 경우라도, 그 수용액의 칼슘 농도는 10 ppm 이상이 된다. 이와 같은 종래의 저메톡실펙틴을 수용액으로 하면, 그것을 상온에서 10 일간 정도 보존하고 있는 동안에 침전물이 생긴다. 그 때문에, 이것을 경장 영양제의 증점제로서 사용하는 자들에게 품질상의 불안을 안겨 버린다. 또, 침전물이 튜브에 부착되면 튜브의 폐색을 일으켜 튜브가 막힐 위험성이 있다. 이에 반하여, 본 발명에서는 펙틴 수용액에 있어서의 칼슘 농도를 9 ppm 이하, 바람직하게는 4.5 ppm 이하로 함으로써, 펙틴 수용액의 보존 중의 침전물 발생을 억제하고 있다.The aqueous solution of pectin of the present invention is also characterized by having a calcium concentration of 9 ppm or less. Conventional low methoxyl pectin having an esterification degree of about 10% contains 1000 ppm or more of calcium, so even if dilute low methoxyl pectin to a 1% by mass aqueous solution, the calcium concentration of the aqueous solution becomes 10 ppm or more. When such a conventional low methoxyl pectin is used as an aqueous solution, a precipitate is formed while it is stored at room temperature for about 10 days. Therefore, quality anxiety is caused to those who use it as a thickener for enteral nutrients. In addition, when a deposit adheres to the tube, there is a risk that the tube is blocked by clogging the tube. On the other hand, in the present invention, by setting the calcium concentration in the aqueous pectin solution to 9 ppm or less, preferably 4.5 ppm or less, generation of precipitates during storage of the pectin aqueous solution is suppressed.
또, 본 발명의 펙틴 수용액은 pH 가 바람직하게는 2 ∼ 8, 보다 바람직하게는 3.5 ∼ 6 이다. pH 가 지나치게 낮아도 지나치게 높아도 보존 중에 펙틴의 저분자화가 일어나, 펙틴의 점도 평균 분자량이 전술한 바람직한 범위를 밑돌 우려가 있기 때문이다.Moreover, the pH of the aqueous solution of pectin of the present invention is preferably 2 to 8, more preferably 3.5 to 6. This is because even if the pH is too low or too high, low molecular weight of pectin occurs during storage, and the viscosity average molecular weight of pectin may fall below the preferred range described above.
본 발명의 펙틴 수용액은 필요에 따라 pH 조정제, 비타민, 미네랄, 증점 다당류, 안정제 등의 임의 성분을 함유할 수 있다.The aqueous solution of pectin of the present invention may contain optional components such as pH adjusters, vitamins, minerals, thickened polysaccharides, and stabilizers, if necessary.
본 발명의 펙틴 수용액의 제조 방법으로는, 예를 들어 시판되는 에스테르화도 5 ∼ 15 ％ 의 저메톡실펙틴을 원료 펙틴으로 하고, 그것을 순수에 용해시킴으로써 펙틴 농도가 1 ∼ 5 질량％ 인 펙틴 수용액을 조제하여, 그 칼슘 농도를 측정한다. 일반적인 펙틴은 칼슘 농도가 높아, 펙틴 농도가 1 ∼ 5 질량％ 인 펙틴 수용액을 조제했을 경우의 펙틴 수용액의 칼슘 농도는 10 ppm 이상이 된다. 이에 반하여, 본 발명에서는 펙틴 농도가 1 ∼ 5 질량％ 인 펙틴 수용액의 칼슘 농도가 9 ppm 을 초과하는 경우에는, 원료 펙틴에 칼슘 저감 처리를 함으로써 동일하게 펙틴 농도 1 ∼ 5 질량％ 로 조제한 펙틴 수용액 중의 칼슘 농도를 9 ppm 이하로 저감시킨다. 한편, 칼슘 농도가 9 ppm 이하인 경우에는, 그 원료 펙틴을 칼슘 저감 처리를 하지 않고 본 발명에서 사용할 수 있는 펙틴으로서 선택한다.As a method for producing the aqueous pectin solution of the present invention, for example, commercially available low methoxyl pectin having a degree of esterification of 5 to 15% is used as the raw material pectin, and by dissolving it in pure water, a pectin aqueous solution having a pectin concentration of 1 to 5 mass% is prepared. Then, the calcium concentration is measured. Normal pectin has a high calcium concentration, and when a pectin aqueous solution having a pectin concentration of 1 to 5 mass% is prepared, the calcium concentration of the pectin aqueous solution becomes 10 ppm or more. On the other hand, in the present invention, when the calcium concentration of the pectin aqueous solution having a pectin concentration of 1 to 5 mass% exceeds 9 ppm, the pectin aqueous solution prepared at a pectin concentration of 1 to 5 mass% is similarly obtained by subjecting the raw material pectin to a calcium reduction treatment. The calcium concentration in the blood is reduced to 9 ppm or less. On the other hand, when the calcium concentration is 9 ppm or less, the raw material pectin is selected as the pectin which can be used in the present invention without subjecting the calcium reduction treatment.
칼슘 저감 처리를 실시한 펙틴, 또는 칼슘 저감 처리가 불필요하다고 하여 선택한 펙틴을 물로 희석시키고, 필요에 따라 가열 처리 혹은 효소 처리를 실시함으로써 펙틴을 저분자화하여 점도 평균 분자량을 10000 ∼ 35000, 바람직하게는 12000 ∼ 27000 으로 조정하여, 펙틴 수용액의 점도가 1 ∼ 30 mPa·s 가 되는 본 발명의 펙틴 수용액을 얻을 수 있다. 혹은, 펙틴 수용액이 상기 서술한 점도가 되도록 펙틴을 물로 희석시킨 후에 칼슘 저감 처리를 실시해도 된다. 또한, 여기서 사용하는 물로는 순수 또는 이온 교환수가 바람직하다.The pectin subjected to the calcium reduction treatment or the pectin selected as the calcium reduction treatment is not necessary is diluted with water, and if necessary, heat treatment or enzyme treatment is performed to lower the molecular weight of the pectin to obtain a viscosity average molecular weight of 10000 to 35000, preferably 12000. By adjusting to ~ 27000, the pectin aqueous solution of the present invention in which the viscosity of the pectin aqueous solution is 1 to 30 mPa · s can be obtained. Alternatively, the calcium reduction treatment may be performed after diluting the pectin with water so that the aqueous pectin solution becomes the above-described viscosity. Moreover, pure water or ion-exchanged water is preferable as the water used here.
여기서, 칼슘 저감 처리로는, 질산 함유 이소프로판올 용액 등의 함수 산성 용매로 세정하는 방법, 이온 교환 수지를 사용하는 방법, 한외 여과막에 의해 여과하는 방법 등을 들 수 있다. 그 중에서도 제조 공정의 번잡함이 적은 점에서, 칼슘 저감 처리로는 이온 교환 수지를 사용하는 방법이 바람직하다.Here, examples of the calcium reduction treatment include a method of washing with a hydrous acid solvent such as a nitric acid-containing isopropanol solution, a method of using an ion exchange resin, and a method of filtering with an ultrafiltration membrane. Among them, a method of using an ion exchange resin is preferable as the calcium reduction treatment from the viewpoint that the manufacturing process is less complicated.
또, 상기 서술한 가열 처리로는, 온도 100 ∼ 145 ℃, 시간 2 ∼ 100 분 동안 가열 가압 처리를 실시하고, 펙틴 수용액을 점도 평균 분자량 10000 ∼ 35000 으로 저분자화하는 것이 바람직하다. 이 가열 가압 처리는 펙틴 수용액을 용기에 충전한 후에 실시해도 된다.Moreover, as the above-mentioned heat treatment, it is preferable to heat-press treatment for 100 to 145 ° C at a temperature and 2 to 100 minutes for a time, and it is preferable to lower the molecular weight of the pectin aqueous solution to a viscosity average molecular weight of 10000 to 35000. This heat pressurization treatment may be performed after filling the container with an aqueous pectin solution.
또, 본 발명의 펙틴 수용액의 제조 공정에 있어서는, 인산, 아세트산, 시트르산 등의 유기산이나 아세트산염, 시트르산염 등의 유기산염, 인산염 등의 pH 조정제의 첨가에 의해 pH 를 2 ∼ 8 로 조정하는 것이 바람직하다.Moreover, in the manufacturing process of the aqueous solution of pectin of the present invention, the pH is adjusted to 2 to 8 by addition of an organic acid such as phosphoric acid, acetic acid, citric acid, or an organic acid salt such as acetate or citrate, or a pH adjusting agent such as phosphate. desirable.
본 발명의 펙틴 수용액은 경장 영양제를 위 내에서 증점시키는 경관 투여용 증점제로서 유용하고, 이 외에 연하 곤란자의 연하를 용이하게 하는 토로미제, 반고형화제 등으로서도 사용할 수 있다.The aqueous solution of pectin of the present invention is useful as a thickener for cervical administration that thickens intestinal nutrients in the stomach, and in addition, it can also be used as a toromyase, a semi-solidifying agent, and the like to facilitate swallowing of people with difficulty swallowing.
실시예Example
이하, 본 발명을 실시예에 기초하여 구체적으로 설명한다.Hereinafter, the present invention will be described in detail based on examples.
실시예 1 ∼ 10, 비교예 1 ∼ 9Examples 1-10, Comparative Examples 1-9
표 1 에 나타내는 바와 같이, 제조자, 제품명 또는 로트가 상이함에 따라, 에스테르화도, 분자량, 칼슘 함유량이 상이한 시판되는 6 종류의 펙틴 (A ∼ G) 을 준비하였다. 또, 시판되는 경장 영양제 증점용 펙틴액 (H) 을 준비하였다 (비교예 9).As shown in Table 1, six types of commercially available pectins (A to G) having different degrees of esterification, molecular weight, and calcium content were prepared according to different manufacturers, product names, or lots. Moreover, a commercially available pectin solution (H) for thickening of enteral nutrients was prepared (Comparative Example 9).
실시예 1 에서는, 에스테르화도가 7 ％ 인 펙틴 A 를 3 질량％ 가 되도록 순수로 용해시켜, 그 100 g 을 내열 용기에 충전 밀봉하고, 온도 110 ℃ 에서 30 분간, 가열 가압 처리함으로써 펙틴 수용액을 제조하였다.In Example 1, an aqueous solution of pectin was prepared by dissolving pectin A having an esterification degree of 7% at 3 mass% with pure water, filling and sealing the 100 g in a heat-resistant container, and heat-pressing at 110 ° C for 30 minutes. Did.
또, 표 1 에 나타내는 원료 펙틴 A ∼ G 를 사용하여 표 1 의 농도의 펙틴 수용액을 조제하고, 펙틴 수용액에 대한 칼슘 저감 처리 또는 펙틴의 저분자화 처리를 표 1 에 기재된 바와 같이 실시하여, 실시예 2 ∼ 10 및 비교예 1 ∼ 8 의 펙틴 수용액을 제조하였다.Moreover, the pectin aqueous solution of the concentration of Table 1 was prepared using the raw materials pectin A-G shown in Table 1, and the calcium reducing treatment or the pectin low molecular weight treatment with respect to the pectin aqueous solution was implemented as shown in Table 1, and an Example The aqueous pectin solutions of 2 to 10 and Comparative Examples 1 to 8 were prepared.
비교예 9 의 펙틴액에 있어서의 펙틴의 정확한 함유량은 불분명하지만, 펙틴 함유량에 상당하는 음식 섬유 함량이 펙틴액 100 g 당 6 g 이다.Although the exact content of pectin in the pectin solution of Comparative Example 9 is unclear, the food fiber content corresponding to the pectin content is 6 g per 100 g of pectin solution.
평가evaluation
각 실시예 및 비교예에서 얻은 펙틴 수용액에 대하여, (a) 제조한 펙틴 수용액의 펙틴의 점도 평균 분자량, (b) 제조한 펙틴 수용액의 점도, (c) 칼슘 농도, (d) 칼슘·나트륨 수용액과의 반응성, (e) pH, (f) 보존 후의 침전물 발생 상태, (g) 경관 투여 증점제로서의 사용하기 용이함, (h) 경장 영양제와의 혼합 점도, (i) 임상 시험을 다음과 같이 측정 혹은 평가하였다. 결과를 표 1 에 나타낸다.For the pectin aqueous solutions obtained in each of the Examples and Comparative Examples, (a) the viscosity average molecular weight of pectin in the prepared pectin aqueous solution, (b) the viscosity of the prepared pectin aqueous solution, (c) calcium concentration, (d) calcium / sodium aqueous solution Reactivity with (e) pH, (f) sediment generation after storage, (g) ease of use as a thickening agent for cervical administration, (h) mixed viscosity with enteral nutrients, (i) clinical trials measured or Was evaluated. Table 1 shows the results.
(a) 펙틴의 점도 평균 분자량(a) Pectin viscosity average molecular weight
극한 점도법에 의해 점도 평균 분자량을 다음과 같이 측정하였다.The viscosity average molecular weight was measured as follows by an infinite viscosity method.
즉, 표 1 의 농도의 펙틴 수용액을 0.2 ㏖/ℓ 농도의 염화나트륨 용액으로 희석시켜 시료 용액을 제조하였다. 구체적으로는 BL 형 점도계 (도키 산업 주식회사 제조) 로터 No. 10, 12 rpm, 25 ℃ 의 조건으로 측정한 점도가 20 mPa·s 미만일 때는, 펙틴 수용액을 40 ㎖, 20 ㎖, 10 ㎖, 5 ㎖, 2.5 ㎖ 정확하게 재서, 각각에 0.2 ㏖/ℓ 농도의 염화나트륨 용액을 첨가하여 정확하게 40 ㎖ 로 한 용액을 시료 용액으로 하였다. 또, BL 형 점도계로 측정한 점도가 20 mPa·s 이상일 때는, 펙틴 수용액을 8 ㎖, 4 ㎖, 2 ㎖, 1 ㎖ 정확하게 재서, 각각에 0.2 ㏖/ℓ 농도의 염화나트륨 용액을 첨가하여 정확하게 40 ㎖ 로 한 용액을 시료 용액으로 하였다. 이 시료 용액 및 0.2 ㏖/ℓ 농도의 염화나트륨 용액 (블랭크) 에 대하여, 일본 약국방 (제 15 개정) 일반 시험법의 점도 측정법 (제 1 법 모세관 점도계법) 에 의해 20.0 ± 0.1 ℃ 에서 비점도를 측정하여 (식 A), 각 농도에 있어서의 환원 점도를 산출하였다 (식 B). 환원 점도를 세로축에, 시료 용액의 펙틴 농도 (g/100 ㎖) 를 가로축에 취하여 그래프를 그리고, 각 점을 연결하는 직선과 세로축의 교점으로부터 극한 점도를 구하였다. 여기서 구해진 극한 점도를 Owens 의 식 (식 C) 에 대입하여 평균 분자량을 산출하였다 (H. S. Owens, H. Lotzkar, T. H. Sxhultz, W. D. Maclay J. Am. Chem. Soc. 1946, 68 (8) 1628-1632).That is, the sample solution was prepared by diluting the aqueous solution of pectin in Table 1 with a sodium chloride solution having a concentration of 0.2 mol / L. Specifically, BL type viscometer (manufactured by Toki Sangyo Co., Ltd.) rotor No. When the viscosity measured under the conditions of 10, 12 rpm, and 25 ° C is less than 20 mPa · s, 40 ml, 20 ml, 10 ml, 5 ml, and 2.5 ml of the pectin aqueous solution are accurately weighed, and sodium chloride at a concentration of 0.2 mol / L in each. The solution was added to exactly 40 ml to make a sample solution. Moreover, when the viscosity measured by a BL type viscometer is 20 mPa · s or more, 8 ml, 4 ml, 2 ml, 1 ml of the pectin aqueous solution is accurately weighed, and 0.2 ml / L sodium chloride solution is added to each to accurately 40 ml. The resulting solution was used as the sample solution. About this sample solution and 0.2 mol / L concentration sodium chloride solution (blank), the specific viscosity is measured at 20.0 ± 0.1 ° C. by the viscosity measurement method (capillary viscometer method of the first method) of the Japanese Pharmacopoeia (Revision 15) general test method. (Formula A), the reduced viscosity at each concentration was calculated (Formula B). The reduced viscosity was plotted on the vertical axis, and the pectin concentration (g / 100 ml) of the sample solution was plotted on the horizontal axis, and the ultimate viscosity was determined from the intersection of the straight line connecting the dots and the vertical axis. The average viscosity was calculated by substituting the intrinsic viscosity obtained here into the equation (Formula C) of Owens (HS Owens, H. Lotzkar, TH Sxhultz, WD Maclay J. Am. Chem. Soc. 1946, 68 (8) 1628-1632 ).
(b) 펙틴 수용액의 점도(b) viscosity of aqueous pectin solution
펙틴 수용액을 BL 형 점도계 (도키 산업 주식회사 제조) 로, 로터 No. 10, 12 rpm, 액온 25 ℃ 에서 측정하였다. 또한, 비교예 8 의 펙틴 수용액은 점도가 50 mPa·s 이상이었기 때문에 6 rpm 으로 측정하고, 비교예 9 의 펙틴액은 0.6 rpm 으로 측정하였다.An aqueous pectin solution was used as a BL-type viscometer (manufactured by Toki Sangyo Co., Ltd.), and the rotor It measured at 10 and 12 rpm, and the liquid temperature at 25 ° C. In addition, since the aqueous solution of pectin of Comparative Example 8 had a viscosity of 50 mPa · s or more, it was measured at 6 rpm, and the pectin solution of Comparative Example 9 was measured at 0.6 rpm.
(c) 펙틴 수용액의 칼슘 농도(c) Calcium concentration of pectin aqueous solution
ICP 발광 분광 분석법에 의해 측정하였다.It was measured by ICP emission spectrometry.
(d) 펙틴 수용액의 칼슘·나트륨 수용액과의 반응성(d) Reactivity of aqueous pectin solution with aqueous calcium / sodium solution
염화칼슘·이수화물 0.019 ㏖/ℓ, 시트르산삼나트륨·이수화물 0.020 ㏖/ℓ 의 칼슘·나트륨 수용액을 조제하였다.An aqueous calcium-sodium solution of 0.019 mol / L calcium chloride / dihydrate and 0.020 mol / L trisodium citrate / dihydrate was prepared.
펙틴 수용액 100 ㎖ 와 칼슘·나트륨 수용액 200 ㎖ 의 합계 300 ㎖ 를 300 ㎖ 비커에 칭량하여, 30 초간 교반하고, 펙틴 수용액과 칼슘·나트륨 수용액을 혼합하고 나서 5 분후의 점도를 BH 형 점도계 (도쿄 계기 주식회사 제조) 로 20 rpm, 액온 25 ℃ 에서 측정하였다.A total of 300 ml of 100 ml of pectin aqueous solution and 200 ml of calcium / sodium aqueous solution were weighed into a 300 ml beaker, stirred for 30 seconds, mixed with the pectin aqueous solution and calcium / sodium aqueous solution, and the viscosity after 5 minutes was measured using a BH viscometer (Tokyo Instruments). It was measured at 20 rpm and a liquid temperature of 25 ° C).
(e) 펙틴 수용액의 pH(e) pH of aqueous pectin solution
메틀러·토레도 (주) 제조 세븐 이지 S20 으로 측정하였다.It measured by the 7 easy S20 by METTLER TOLEDO Corporation.
(f) 보존 후의 침전물 발생(f) Sediment generation after storage
펙틴 수용액을 제조 후, 60 ℃ 에서 4 주간 보존하여 침전물 발생의 유무를 육안으로 관찰하고, 다음의 기준으로 평가하였다.After the aqueous pectin solution was prepared, it was stored at 60 ° C for 4 weeks to observe the presence or absence of sediment, and evaluated according to the following criteria.
◎ ： 침전물은 발생하지 않음◎ ： No sediment occurs
○ ： 약간 침전물 발생이 관찰되지만, 문제없는 정도○: Slight sediment formation is observed, but there is no problem.
× ： 침전물이 대량으로 발생함×: A large amount of sediment is generated
(g) 경관 투여 증점제로서의 사용하기 용이함(g) Easy to use as thickener for cervical administration
펙틴 수용액을 50 ㎖ 시린지로, 굵기 8 Fr. 길이 90 cm 의 영양 튜브 (주식회사 JMS 제조) 에 주입하여, 압출 용이함을 다음의 기준으로 평가하였다.An aqueous pectin solution was used in a 50 ml syringe, and the thickness was 8 Fr. It was injected into a 90 cm long nutrition tube (manufactured by JMS Co., Ltd.) to evaluate the ease of extrusion based on the following criteria.
◎ ： 매우 주입하기 용이함◎ ： Very easy to inject
○ ： 저항감은 있지만, 문제없이 주입할 수 있음○: There is a feeling of resistance, but it can be injected without problems.
× ： 뻑뻑하여 시린지를 밀어넣을 수 없어 주입할 수 없음× ： It is stiff and cannot be injected because the syringe cannot be pushed.
(h) 경장 영양제와의 혼합 시험(h) Mixing test with enteral nutrients
500 ㎖ 비커에 펙틴 수용액 100 ㎖ 를 넣고, 거기에 나트륨 함량이 상이한 시판되는 경장 영양제 2 종 (쟈네후 K-4S 또는 쟈네후 K-LEC, 큐피 주식회사 제조) 400 ㎖ 를 첨가하여 30 초간 교반하고, 펙틴 수용액과 경장 영양제를 혼합하고 나서 5 분후의 점도를 BH 형 점도계 (도쿄 계기 주식회사 제조) 로, 로터 No. 2, 20 rpm, 액온 25 ℃ 에서 측정하였다. 또한, 비교예 9 의 펙틴액을 쟈네후 K-4S 와 혼합한 경우에는, BH 형 점도계의 로터 No. 3 을 사용하고, 쟈네후 K-LEC 와 혼합한 경우에는, BH 형 점도계의 로터 No. 4 를 사용하였다.100 ml of a pectin aqueous solution was added to a 500 ml beaker, and 400 ml of commercially available enteric nutrients with different sodium contents (Janefu K-4S or Janefu K-LEC, manufactured by Kewpie Co., Ltd.) were added and stirred for 30 seconds, After mixing the aqueous pectin solution and the enteric nutrient, the viscosity after 5 minutes was measured using a BH-type viscometer (manufactured by Tokyo Instruments Co., Ltd.). It measured at 2, 20 rpm, and the liquid temperature of 25 ° C. In addition, when the pectin solution of Comparative Example 9 was mixed with Janef K-4S, the rotor No. of the BH viscometer was used. When 3 is used and mixed with Kenneth K-LEC, rotor No. of the BH viscometer is used. 4 was used.
여기서, 사용한 경장 영양제의 칼슘 함량과 나트륨 함량은 다음과 같다.Here, the calcium content and sodium content of the intestinal nutrient used are as follows.
쟈네후 K-4S Janefu K-4S
Ca 함량 ： 60 ㎎/100 ㎖ Ca content: 60 mg / 100 ml
Na 함량 ： 180 ㎎/100 ㎖ Na content: 180 mg / 100 ml
쟈네후 K-LEC Janefu K-LEC
Ca 함량 ： 60 ㎎/100 ㎖ Ca content: 60 mg / 100 ml
Na 함량 ： 80 ㎎/100 ㎖ Na content: 80 mg / 100 ml
(i) 임상 시험(i) Clinical trial
경장 영양제 (칼슘 농도 60 ㎎/100 ㎖, 나트륨 농도 180 ㎎/100 ㎖) 를 투여받고, 설사나 구토의 증상이 있는 환자에 대하여 경장 영양제의 투여시에, 그 경장 영양제 400 ㎖ 에 대하여 본 발명의 펙틴 수용액 약 100 ㎖ 를 3 일간 투여하여 증상의 개선 유무를 조사하고, 다음의 기준으로 평가하였다.When enteral nutrients are administered to patients with diarrhea or vomiting symptoms who are administered enteral nutrients (calcium concentration 60 mg / 100 ml, sodium concentration 180 mg / 100 ml), 400 ml of the enteral nutrients of the present invention About 100 ml of pectin aqueous solution was administered for 3 days to investigate whether symptoms improved or not, and evaluated according to the following criteria.
○ ： 구토나 설사의 증상이 개선됨○ ： Symptoms of vomiting and diarrhea improved.
× ： 구토나 설사의 증상이 개선되지 않음×: Symptoms of vomiting and diarrhea did not improve
표 1 로부터, 본 발명의 각 실시예의 펙틴 수용액은 펙틴의 에스테르화도가 5 ∼ 15 ％ 의 범위에 있고, 또한 펙틴의 점도 평균 분자량이 10000 ∼ 35000 의 범위에 있으므로, 칼슘·나트륨 수용액을 충분히 증점시킬 수 있는 것을 알 수 있다. 또한, 이들 실시예에서는, 가열 가압 처리에 의해 (실시예 1 ∼ 8, 10), 혹은 효소 처리에 의해 (실시예 9), 분자량의 저분자화가 실시되고 있다.From Table 1, the aqueous solution of pectin of each example of the present invention has a degree of esterification of pectin in the range of 5 to 15%, and the viscosity average molecular weight of pectin is in the range of 10000 to 35000. You can see what you can do. Moreover, in these Examples, molecular weight reduction is performed by heat and pressure treatment (Examples 1 to 8 and 10) or by enzyme treatment (Example 9).
또한, 실시예 1 의 펙틴 수용액은, 나트륨이 많은 경장 영양제 (K-4S) 와 적은 경장 영양제 (K-LEC) 의 어느 쪽이라도 증점시킬 수 있었기 때문에, 본 발명의 각 실시예는 나트륨 함량이 많고 적은 것에 관계없이 경장 영양제를 증점시킬 수 있는 것을 알 수 있다.In addition, since the aqueous solution of pectin of Example 1 was able to thicken either the sodium-rich enteric nutrient (K-4S) or the small enteric nutrient (K-LEC), each example of the present invention had a high sodium content. It can be seen that the intestinal nutrient can be thickened regardless of the small amount.
또, 이들 실시예는, 원료가 되는 펙틴으로서 칼슘 함량이 낮은 것을 선택함으로써 펙틴 수용액에 칼슘 저감 처리를 하지 않고, 펙틴 수용액 중의 칼슘 농도를 9 ppm 이하로 한 것이나 (실시예 1 ∼ 7, 9), 이온 교환 수지의 사용에 의해 칼슘 농도를 저감시켜 펙틴 수용액 중의 칼슘 농도를 9 ppm 이하로 한 것 (실시예 8, 10) 으로, 모두 보존 후에 문제가 될 정도의 양의 침전물은 발생하지 않았다. 특히, 펙틴 수용액 중의 칼슘 농도가 4.5 ppm 이하이면 (실시예 1 ∼ 5, 7 ∼ 9), 침전물이 발생하지 않는 것을 알 수 있다.In addition, these examples did not perform a calcium reduction treatment to the pectin aqueous solution by selecting a pectin serving as a raw material with a low calcium content, and the calcium concentration in the pectin aqueous solution was 9 ppm or less (Examples 1 to 7, 9). , The calcium concentration was reduced by the use of an ion exchange resin so that the calcium concentration in the pectin aqueous solution was 9 ppm or less (Examples 8 and 10), and no precipitate was generated in an amount that would be problematic after storage. In particular, it can be seen that if the calcium concentration in the aqueous pectin solution is 4.5 ppm or less (Examples 1 to 5, 7 to 9), no precipitate was generated.
이에 반하여, 점도 평균 분자량이 35000 을 초과하는 비교예 1 에서는 칼슘·나트륨 수용액과의 반응에서 강고한 겔이 형성되고, 그 점도는 측정이 불가능하였다. 따라서, 비교예 1 의 펙틴 수용액을 위 내에서 경장 영양제와 혼합하면, 위 내에 강고한 겔이 형성되어 소화 흡수가 충분히 이루어지지 않아, 경장 영양제의 영양을 필요량 흡수할 수 없는 폐해가 생기는 것으로 생각된다.On the other hand, in Comparative Example 1 in which the viscosity average molecular weight was more than 35000, a strong gel was formed in reaction with an aqueous solution of calcium and sodium, and its viscosity could not be measured. Therefore, when the aqueous solution of pectin of Comparative Example 1 is mixed with the enteral nutrient in the stomach, a strong gel is formed in the stomach and digestion and absorption is not sufficiently achieved, and it is thought that the nutrients cannot absorb the nutritional value of the enteral nutrient. .
한편, 비교예 5 의 펙틴 수용액은, 에스테르화도가 15 ％ 를 초과함으로써 칼슘·나트륨 수용액과 반응성이 낮아, 나트륨 함유량이 많은 경장 영양제 (K-4S) 뿐만 아니라, 나트륨 함유량이 적은 경장 영양제 (K-LEC) 도 충분히 증점시킬 수 없었다.On the other hand, the aqueous solution of pectin of Comparative Example 5 has a low reactivity with an aqueous solution of calcium and sodium because the degree of esterification exceeds 15%, and not only a enteric nutrient with high sodium content (K-4S), but also a enteric nutrient with low sodium content (K- LEC) was also unable to thicken sufficiently.
비교예 6, 7, 8 의 펙틴 수용액에서도 에스테르화도가 15 ％ 를 초과하는 펙틴을 원료로 하였다. 이 중 비교예 6 에서는, 저분자화 처리 후의 점도 평균 분자량이 35000 을 초과하였지만, 에스테르화도가 높음으로써 칼슘·나트륨 수용액을 충분히 증점시킬 수 없었다. 비교예 7 에서는 가열 처리에 의한 저분자화를 실시하지 않았기 때문에, 칼슘·나트륨 수용액을 충분히 증점시킬 수는 있었지만, 펙틴 수용액 자체의 점도가 30 mPa·s 를 초과함으로써 그것을 영양 튜브에 주입할 수 없었다. 또, 비교예 8 에서는 펙틴 수용액 중의 펙틴 함량을 높임으로써 칼슘·나트륨 수용액과의 반응성을 높이려고 한 것이지만, 펙틴 수용액 자체의 점도가 30 mPa·s 를 초과하여 그것을 영양 튜브에 주입할 수 없었다.Even in the pectin aqueous solutions of Comparative Examples 6, 7, and 8, pectin having an esterification degree of more than 15% was used as a raw material. Among these, in Comparative Example 6, the viscosity average molecular weight after the low molecular weight treatment exceeded 35000, but the calcium / sodium aqueous solution could not be sufficiently thickened due to the high degree of esterification. In Comparative Example 7, the low-molecularization by heat treatment was not performed, so that the aqueous solution of calcium and sodium could be sufficiently thickened, but the viscosity of the pectin aqueous solution itself exceeded 30 mPa · s, so that it could not be injected into the nutrient tube. Further, in Comparative Example 8, the pectin content in the aqueous pectin solution was increased to increase the reactivity with the aqueous calcium / sodium solution, but the viscosity of the pectin aqueous solution itself exceeded 30 mPa · s and it could not be injected into the nutrient tube.
한편, 비교예 2 에서는, 실시예 1 과 동일한 펙틴을 원료로 했지만, 그 함유량을 높임으로써 펙틴 수용액 자체의 점도가 30 mPa·s 를 초과하여 그것을 영양 튜브에 주입할 수 없었다.On the other hand, in Comparative Example 2, the same pectin as in Example 1 was used as a raw material, but by increasing the content, the viscosity of the pectin aqueous solution itself exceeded 30 mPa · s and it could not be injected into the nutrient tube.
또, 수용액 중의 칼슘 농도가 9 ppm 을 초과하는 비교예 2 ∼ 4, 6 ∼ 9 에서는, 모두 보존 후에 침전물이 발생하였다. 이 중 비교예 2, 3 은 실시예 1 과 동일한 펙틴을 원료로 한 것이지만, 비교예 2 에서는 원료 펙틴의 함유량을 높임으로써 펙틴 수용액 중의 칼슘 농도가 높아지고, 또 비교예 3 에서는 희석수에 수돗물을 했기 때문에, 수돗물 중에 함유되는 칼슘에 의해 펙틴 수용액 중의 칼슘 농도가 높아져 각각 침전물이 발생한 것으로 생각된다. 비교예 9 의 시판되는 경장 영양제 증점용 펙틴액의 칼슘 농도가 실시예 1 ∼ 10 보다 10 배 이상 높은 것을 알 수 있다.In addition, in Comparative Examples 2 to 4 and 6 to 9 in which the calcium concentration in the aqueous solution exceeded 9 ppm, precipitates were generated after storage. Among these, Comparative Examples 2 and 3 were made from the same pectin as Example 1, but in Comparative Example 2, the content of the raw material pectin was increased to increase the calcium concentration in the aqueous pectin solution, and in Comparative Example 3, tap water was added to the diluted water. Therefore, it is considered that the calcium concentration in the pectin aqueous solution is increased by calcium contained in the tap water, and precipitates are generated respectively. It can be seen that the calcium concentration of the commercially available pectin solution for thickening the enteric nutrient of Comparative Example 9 is 10 times higher than Examples 1 to 10.
산업상 이용가능성Industrial availability
본 발명의 펙틴 수용액은 경장 영양제의 증점제, 연하 보조 식품으로서의 토로미제, 반고형화제로서 사용할 수 있다.The aqueous solution of pectin of the present invention can be used as a thickening agent for enteric nutrients, a toromise as a swallowing aid, and a semi-solidifying agent.
Claims (11)
펙틴의 함유량이 1 ∼ 5 질량％ 인 펙틴 수용액.According to claim 1,
A pectin aqueous solution having a pectin content of 1 to 5% by mass.
pH 가 2 ∼ 8 인 펙틴 수용액.According to claim 1,
An aqueous pectin solution with a pH of 2 to 8.
칼슘 저감 처리가 이루어져 있는 펙틴 수용액.According to claim 1,
An aqueous solution of pectin with calcium reduction treatment.
위 내에서 경장 영양제를 증점시키기 위해서 사용하는 경관 투여용 증점제.The method of claim 5,
A thickener for cervical administration used to thicken enteric nutrients in the stomach.
에스테르화도 5 ∼ 15 ％ 의 펙틴으로서, 그 펙틴을 물로 희석시켜 펙틴 함유량 1 ∼ 5 질량％ 의 펙틴 수용액을 조제했을 경우에, 그 펙틴 수용액의 칼슘 농도가 9 ppm 을 초과했을 때, 펙틴에 칼슘 저감 처리를 실시하고, 동일하게 조제한 펙틴 수용액의 칼슘 농도가 9 ppm 이하가 되는 것을 원료 펙틴으로 하는 펙틴 수용액의 제조 방법.The method of claim 7,
As a pectin having an esterification degree of 5 to 15%, dilute the pectin with water to prepare a pectin aqueous solution having a pectin content of 1 to 5% by mass, and when the calcium concentration of the pectin aqueous solution exceeds 9 ppm, calcium is reduced in pectin. A method for producing a pectin aqueous solution using the raw material pectin in which the calcium concentration of the pectin aqueous solution prepared in the same manner as the treatment is 9 ppm or less.
점도 평균 분자량 10000 ∼ 35000 이 되도록 저분자화 처리를 실시하는 펙틴 수용액의 제조 방법.The method of claim 7,
The manufacturing method of the aqueous solution of pectin which performs low molecular weight treatment so that it may become a viscosity average molecular weight of 10000-35000.
저분자화 처리로서 온도 100 ∼ 145 ℃, 가열 가압 처리를 2 ∼ 100 분 실시하는 펙틴 수용액의 제조 방법.The method of claim 9,
The manufacturing method of the aqueous solution of pectin which performs a temperature 100-145 degreeC as a low molecular weight treatment, and heat-pressurization treatment for 2 to 100 minutes.
pH 2 ∼ 8 로 조정하는 펙틴 수용액의 제조 방법.The method of claim 7,
A method for producing a pectin aqueous solution adjusted to pH 2-8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012153873 | 2012-07-09 | ||
| JPJP-P-2012-153873 | 2012-07-09 | ||
| PCT/JP2013/068714 WO2014010577A1 (en) | 2012-07-09 | 2013-07-09 | Aqueous pectin solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150028239A KR20150028239A (en) | 2015-03-13 |
| KR102100103B1 true KR102100103B1 (en) | 2020-04-13 |
Family
ID=49916029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147034505A KR102100103B1 (en) | 2012-07-09 | 2013-07-09 | Aqueous pectin solution |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5505577B1 (en) |
| KR (1) | KR102100103B1 (en) |
| CN (1) | CN103974723B (en) |
| HK (1) | HK1200725A1 (en) |
| WO (1) | WO2014010577A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105664170A (en) * | 2016-01-23 | 2016-06-15 | 杭州吉为医疗科技有限公司 | Amidated low-ester pectin composition and method for preparing same |
| AU2017284391B2 (en) * | 2016-06-17 | 2022-11-17 | Otsuka Pharmaceutical Factory, Inc. | Diarrhea-preventing nutritional composition |
| CN107594483A (en) * | 2017-01-13 | 2018-01-19 | 江苏西宏生物医药有限公司 | A kind of pectin solution of stabilization |
| CN107518411A (en) * | 2017-01-13 | 2017-12-29 | 江苏西宏生物医药有限公司 | A kind of anti-diarrhea enteral nutrition composition |
| CN107616983A (en) * | 2017-01-13 | 2018-01-23 | 江苏西宏生物医药有限公司 | A kind of anti-diarrhea enteral nutrition composition |
| CN107616984A (en) * | 2017-01-13 | 2018-01-23 | 江苏西宏生物医药有限公司 | A kind of anti-diarrhea enteral nutrition composition |
| CN107468702A (en) * | 2017-09-18 | 2017-12-15 | 浙江大学 | Pectin solution for treating antibiotic-associated diarrhea and preparation method thereof |
| CN109007859A (en) * | 2018-10-10 | 2018-12-18 | 纽湃腾（北京）医药科技有限公司 | A kind of stable carbohydrate composition aqueous solution and preparation method and application |
| CN111166717B (en) * | 2019-07-17 | 2022-01-04 | 江苏西宏生物医药有限公司 | Thermostable enteral nutrient solution |
| CN110558564A (en) * | 2019-09-05 | 2019-12-13 | 浙江大学 | Gastrointestinal nutrition digestion and absorption regulator |
| CN111493326A (en) * | 2020-04-28 | 2020-08-07 | 成都尚医信息科技有限公司 | Enteral nutrition food and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000504772A (en) | 1996-02-15 | 2000-04-18 | ハーキュリーズ・インコーポレイテッド | Pectin fiber |
| JP2004503613A (en) | 2000-06-09 | 2004-02-05 | シーピー・ケルコ・エイピーエス | Low methoxyl pectin, method for producing the same, and stabilized aqueous system comprising the same |
| JP2006248981A (en) | 2005-03-10 | 2006-09-21 | En Otsuka Pharmaceutical Co Ltd | Gelatinizer for nutritive preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173377B1 (en) * | 1998-01-20 | 2000-09-11 | Hercules Inc | Pectin for use in paste-like materials, process for making them, paste-like materials comprising pecti |
| WO2000013529A1 (en) | 1998-09-09 | 2000-03-16 | Kewpie Kabushiki Kaisha | Foods for preventing vomiting |
| JP3140426B2 (en) | 1999-01-28 | 2001-03-05 | キユーピー株式会社 | Anti-dumping food |
| CN100497397C (en) * | 2003-07-07 | 2009-06-10 | Kmc卡特费尔美尔中心有限公司 | Method for preparing fibre-containing pectin and products and uses hereof |
-
2013
- 2013-07-09 JP JP2013553705A patent/JP5505577B1/en active Active
- 2013-07-09 CN CN201380004157.5A patent/CN103974723B/en active Active
- 2013-07-09 WO PCT/JP2013/068714 patent/WO2014010577A1/en active Application Filing
- 2013-07-09 KR KR1020147034505A patent/KR102100103B1/en active IP Right Grant
-
2015
- 2015-02-05 HK HK15101281.9A patent/HK1200725A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000504772A (en) | 1996-02-15 | 2000-04-18 | ハーキュリーズ・インコーポレイテッド | Pectin fiber |
| JP2004503613A (en) | 2000-06-09 | 2004-02-05 | シーピー・ケルコ・エイピーエス | Low methoxyl pectin, method for producing the same, and stabilized aqueous system comprising the same |
| JP2006248981A (en) | 2005-03-10 | 2006-09-21 | En Otsuka Pharmaceutical Co Ltd | Gelatinizer for nutritive preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150028239A (en) | 2015-03-13 |
| JPWO2014010577A1 (en) | 2016-06-23 |
| CN103974723B (en) | 2015-11-25 |
| WO2014010577A1 (en) | 2014-01-16 |
| JP5505577B1 (en) | 2014-05-28 |
| CN103974723A (en) | 2014-08-06 |
| HK1200725A1 (en) | 2015-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102100103B1 (en) | Aqueous pectin solution | |
| EP1800663B1 (en) | Enteral nutrient | |
| CN101836953B (en) | Ambroxol hydrochloride composition injection | |
| US11419940B2 (en) | Composition as auxiliary means for oral medication | |
| CN109007859A (en) | A kind of stable carbohydrate composition aqueous solution and preparation method and application | |
| JP6134156B2 (en) | Antidiarrheal composition | |
| JP7090641B2 (en) | Suspension containing aluminum hydroxide and magnesium hydroxide and its manufacturing method | |
| CN109364098A (en) | PH neutral peritoneal dialysis solution and its preparation process | |
| CN108853476A (en) | A kind of iron protein succinylate oral solution and preparation method thereof | |
| CN105476954A (en) | Lomefloxacin hydrochloride injection and preparation method thereof | |
| CN110200905A (en) | A kind of ambroxol hydrochloride composition and its injection and application | |
| EP3763358A1 (en) | Suspending vehicle formulation | |
| CN103859058B (en) | The high stability composition of a kind of whey protein | |
| CN101972257A (en) | Medicine composite containing moxifloxacin | |
| CN101697973B (en) | Cefathiamidine preparation for injection and preparation method thereof | |
| CN104013643A (en) | Compound electrolyte invert sugar injection liquid | |
| KR101486534B1 (en) | Oral preparation and preparation method of the same | |
| CN104983678A (en) | Ornidazole infusion preparation and preparation technology thereof | |
| CN103405392B (en) | Special injection for sodium fusidate freeze-dried powder injection, and preparation method of special injection | |
| CN107875187A (en) | A kind of medicinal composition for injections of phaseolin | |
| CN103110592B (en) | Freeze-drying composition for injection and preparation method thereof | |
| CN103536528B (en) | Riboflavin sodium phosphate injection and preparation process thereof | |
| CN107737101A (en) | A kind of medicinal composition for injections of decanoy acetaldehyde | |
| CN106361855A (en) | Method for preparing pharmaceutical composition of Yinzhihuang injection | |
| CN105362215A (en) | Calcium lactate oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| N231 | Notification of change of applicant | ||
| GRNT | Written decision to grant |